Repligen Stock
Repligen Corporation
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- Olivier Loeillot
- Employees
- 2,000
- Market cap
- $11.1 B
- IPO
- 29/04/1986
Repligen Corporation is a healthcare company headquartered in Waltham, US, specializing in the creation and distribution of advanced bioprocessing technologies and integrated systems. Founded in 1981, the corporation provides solutions vital for various stages of biological drug production. Its diverse clientele…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Repligen stock: price history
1D
-4.8%
1W
+0.9%
1M
+1.5%
6M
+33.7%
YTD
+7.1%
1Y
+13.5%
2Y
+27.0%
5Y
-34.3%
10Y
+498.3%
Next earnings date
Next earnings date
27/10/2026 (in 10 days)
Volatility around earnings
~31% stronger price swings than usual
Repligen stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
1 more assignment (Enabler/Second row) Pro-only.
Repligen Corporation is a provider of technologies and systems for bioprocessing. The portfolio comprises specialized components such as protein purification solutions, chromatography resins, filtration systems, and process analytics solutions. The products are used in the manufacturing of biopharmaceuticals, for example in purification or cell culture applications. Customer groups include pharmaceutical companies, research institutions, and contract manufacturers across various global markets. The business model combines the sale of specialized equipment with the continuous demand for highly specialized consumables within complex bioprocess workflows.
- Revenue model
- Mixed
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Switching costs
- Capital intensity
- Low
- Customer concentration
- Unknown
Ask the agents about Repligen
Analyst assessment of Repligen
PRICE TARGET LOW
US$142.00
CONSENSUS
US$173.86
MEDIAN
US$160.00
PRICE TARGET HIGH
US$225.00
1
STRONG BUY
21
BUY
2
HOLD
0
SELL
0
STRONG SELL
24
TOTAL · Buy
As of: 07/10/2026
Repligen stock metrics
P/E
237.05
P/B
4.68
EV/EBITDA
64.2
RETURN ON EQUITY
0.2%
NET MARGIN
2.5%
DEBT/EQUITY
0.33
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
84.2%
FLOAT SHARES
53,472,751
AVG. DAILY VOLUME (30D)
1,209,812
Insider transactions (SEC)
Douglass Brian Robb
Loeillot Olivier
Loeillot Olivier
Loeillot Olivier
Loeillot Olivier
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.8%
Forums (Reddit)
Institutional holders
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Repligen stock
What does Repligen do?
Repligen Corporation is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Olivier Loeillot, the company employs around 2,000 people.
The IPO was on 29/04/1986; the stock trades on NASDAQ under the ticker RGEN.
What do analysts say about Repligen stock?
24 analysts rate the stock, the consensus is Buy (as of 07/10/2026).
The average price target is US$173.86, ranging from US$142.00 to US$225.00, with a median of US$160.00.
This is an external assessment, not a statement by Market Jury.
When does Repligen report next?
The next earnings date is 27/10/2026.
Around past earnings, price swings were roughly 31% stronger than usual.
Does Repligen pay a dividend?
No, Repligen currently does not pay a dividend.
Which stocks are comparable to Repligen?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
How can I get Repligen stock analyzed?
Clicking "Analyze stock" lets five strategies assess Repligen against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.